Idiopathic pulmonary fibrosis (IPF): cross-border specialty drug access for international patients

Quick orientation

Idiopathic pulmonary fibrosis affects an estimated 13 to 20 per 100,000 people globally, with higher prevalence in older adults.

Typical age of onset. Most commonly diagnosed in adults aged 60 and older.

Severity tiers. IPF is progressive with a median survival of 3 to 5 years from diagnosis without treatment. Antifibrotic therapy slows decline but does not reverse disease.

Why specialty drugs for Idiopathic pulmonary fibrosis (IPF) are hard to access internationally

Two antifibrotic agents (pirfenidone, nintedanib) are widely registered globally. Newer FDA approvals such as Ohtuvayre (ensifentrine) for COPD and emerging IPF-specific agents are not yet broadly registered.

Treatments approved by the FDA

• Ohtuvayre (ensifentrine) — FDA approval: 2024. Mechanism: Dual PDE3/PDE4 inhibitor (COPD label; adjacent respiratory mechanism). Route: Nebulized twice daily. US WAC ballpark: Approximately USD 30,000 per year. Country pricing: UAE · Saudi Arabia · Oman · Lebanon.
• Esbriet (pirfenidone) — FDA approval: 2014. Mechanism: Antifibrotic agent. Route: Oral three times daily. US WAC ballpark: Approximately USD 100,000 per year.
• Ofev (nintedanib) — FDA approval: 2014. Mechanism: Tyrosine kinase inhibitor with antifibrotic activity. Route: Oral twice daily. US WAC ballpark: Approximately USD 110,000 per year.

Cross-border pathways used for Idiopathic pulmonary fibrosis (IPF)

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Personal Import Scheme
• Cross-border Prescription

What your physician needs to know

• Confirm IPF diagnosis by multidisciplinary discussion incorporating HRCT and clinical context.
• Document baseline pulmonary function tests.
• Liver function monitoring is required for both antifibrotic agents.
• Pulmonologist co-management is essential.
• Counsel on photosensitivity (pirfenidone) and gastrointestinal effects (both agents).

Common questions

Will antifibrotics improve my lung function?

They slow decline rather than improve function. Earlier initiation is generally favored.

Are they available locally?

Pirfenidone and nintedanib are widely registered. Newer agents have narrower footprints.

What about lung transplant?

Transplant referral is recommended for eligible patients with progressive disease.

How long does shipment take?

Five to ten business days from prescription receipt.

What documents are required?

Pulmonologist's prescription, HRCT report, PFTs, and clinical summary.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Idiopathic pulmonary fibrosis (IPF), our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Idiopathic pulmonary fibrosis (IPF)

Reserved for you.